Radioimmunotherapy with 90Y Ibritumumab Tiuxetan in B-cell CD20+ indolent non-Hodgkin Lymphoma: A retrospective study

Foundation for the Study of hematology in Aragon [Fundación para el Estudio de la Hematologia y Hemoterapia en Aragón](FEHHA)0 个研究点目标入组 50 人2013年4月10日

概览

阶段: 不适用
干预措施: 未指定
疾病 / 适应症: 未指定
发起方: Foundation for the Study of hematology in Aragon [Fundación para el Estudio de la Hematologia y Hemoterapia en Aragón](FEHHA)
入组人数: 50
状态: 已完成
最后更新: 11年前

概览研究者入排标准结局指标相似试验

概览

简要总结

暂无简介。

注册库

who.int

开始日期

2013年4月10日

结束日期

待定

最后更新

11年前

研究类型

Interventional

性别

All

研究者

发起方

Foundation for the Study of hematology in Aragon [Fundación para el Estudio de la Hematologia y Hemoterapia en Aragón](FEHHA)

入排标准

入选标准

•1\. Adults patients with an excisional biopsy\-confirmed diagnosis of CD20\+ F\-NHL grade 1, 2, or 3a according to the revised WHO classification system
•2\. ECOG performance status \= 2
•3\. Absolute neutrophil count (ANC) \= 1,500/µL
•4\. Absolute platelet count (APC) \= 100,000/µL
•5\. Bone marrow total lymphocytes \= 25% by morphological counting
•6\. Serum bilirubin \= 2\.0mg/dL and serum creatinine \= 2\.0mg/dL
•7\. All patients were requested to sign an informed consent form

排除标准

•1\. Presence of any other malignancy or history of prior malignancy within 5 years of study entry. This does not apply to\-non melanoma skin tumors and in situ cervical cancer.
•2\. Prior radioimmunotherapy
•3\. Presence of primary central nervous system (CNS) lymphoma at first diagnosis
•4\. Known seropositivity for hepatitis C virus (HCV) or hepatitis B surface antigen (HbsAg).
•5\. Known history of HIV infection
•6\. Abnormal liver function: total bilirubin \> 2 × ULN unless secondary to Gilbert disease.
•7\. Abnormal renal function: serum creatinine \> 2\.0 × ULN
•8\. Ongoing toxic effects of chemotherapy \> grade 2 and expected to interfere with Zevalin® treatment.

结局指标

主要结局

未指定

相似试验

已完成

不适用

Retrospective Analysis on Relapsed/Refractory Aggressive Non Hodgkin Lymphoma Treated With Z-BEAM Plus ASCTRefractory B-Cell Non-Hodgkin LymphomaRecurrent B-Cell Non-Hodgkin Lymphoma

NCT02992223A.O.U. Città della Salute e della Scienza58

已完成

1 期

Yttrium Y 90 Ibritumomab Tiuxetan and Rituximab in Treating Patients With Post-Transplant Lymphoproliferative DisorderPost-transplant Lymphoproliferative DisorderRecurrent Adult Burkitt LymphomaRecurrent Adult Diffuse Large Cell LymphomaStage III Adult Burkitt LymphomaStage III Adult Diffuse Large Cell LymphomaStage IV Adult Burkitt LymphomaStage IV Adult Diffuse Large Cell LymphomaWaldenström Macroglobulinemia

NCT00064246National Cancer Institute (NCI)28

已完成

3 期

Treatment With [90]Y-Ibritumomab Tiuxetan Versus no Treatment in Patients With Follicular Non Hodgkin Lymphoma (Stage III or IV) Having Achieved a Partial or Complete Remission After First Line ChemotherapyLymphoma, Non-Hodgkin

NCT00185393Bayer414

终止

1 期

Radiolabeled Monoclonal Antibody With or Without Peripheral Stem Cell Transplantation in Treating Children With Recurrent or Refractory LymphomaAIDS-related Peripheral/Systemic LymphomaAIDS-related Primary CNS LymphomaPost-transplant Lymphoproliferative DisorderRecurrent Childhood Large Cell LymphomaRecurrent Childhood Lymphoblastic LymphomaRecurrent Childhood Small Noncleaved Cell LymphomaRecurrent/Refractory Childhood Hodgkin Lymphoma

NCT00036855National Cancer Institute (NCI)36

进行中（未招募）

1 期

Phase II study of 90Y ibritumomab tiuxetan (Zevalin) in patients with untreated follicular non-Hodgkin's lymphoma. - ZEUS

EUCTR2006-006808-11-ITAZIENDA OSPEDALIERA UNIVERSITARIA SAN MARTINO GENOVA